VALENCIA, Calif.--(BUSINESS WIRE)--Bioness Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its L300® Foot Drop System to pediatric ...
VALENCIA, Calif.--(BUSINESS WIRE)--Bioness, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the StimRouter®, an implantable neuromodulation device designed to treat chronic ...
New device advancements build on the global success of L300® and help improve mobility of stroke survivors and individuals with upper motor neuron pathologies VALENCIA, Calif., April 25, 2017 ...
VALENCIA, Calif., Oct. 1, 2025 /PRNewswire/ — Bioness Medical, Inc., a leading neuro-rehabilitation Company that is innovating to improve and restore function for those living with neurological ...
The US Food and Drug Administration (FDA) has approved the L300 Foot Drop System (Bioness) for use in children with neurologic conditions such as cerebral palsy, multiple sclerosis, stroke, or ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Neurostimulation is clinically effective and cost efficient, but it's not being used appropriately in many patients with chronic pain, according to experts in the field who are addressing current gaps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results